Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease

Objective This prospective study aimed to evaluate the safety of improved transurethral plasma kinetic enucleation of the prostate (iTUPKEP) in the perioperative period in high-risk patients with benign prostatic hyperplasia (BPH) and coronary artery disease. Methods Patients with BPH underwent surg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qingchao Meng, Jingmei Li, Mingfeng Li, Rangxue Qiu
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b7217ca13acf41048fd4d54bde72cede
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7217ca13acf41048fd4d54bde72cede
record_format	dspace
spelling	oai:doaj.org-article:b7217ca13acf41048fd4d54bde72cede2021-12-02T08:04:17ZEvaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease1473-230010.1177/03000605211060890https://doaj.org/article/b7217ca13acf41048fd4d54bde72cede2021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211060890https://doaj.org/toc/1473-2300Objective This prospective study aimed to evaluate the safety of improved transurethral plasma kinetic enucleation of the prostate (iTUPKEP) in the perioperative period in high-risk patients with benign prostatic hyperplasia (BPH) and coronary artery disease. Methods Patients with BPH underwent surgical treatment with transurethral vapour resection of the prostate (TUVP) or iTUPKEP. Serum endothelin-1, cardiac troponin-I, and high-sensitivity C-reactive protein concentrations were evaluated in the short term after surgery. The postvoid residual urine volume, maximum urinary flow rate, international prostate symptom score, and quality of life indicators were evaluated in the long term after surgery. Results Endothelin-1 concentrations were lower in the iTUPKEP group than in the TUVP group at 1 and 2 days postoperatively. The iTUPKEP group had lower cardiac troponin-I and high-sensitivity C-reactive protein concentrations at all time points postoperatively. The postvoid residual urine volume, international prostate symptom score, and quality of life values were lower, but the maximum urinary flow rate was higher, in the iTUPKEP group than in the TUVP group. Conclusions The iTUPKEP procedure has a smaller effect on vascular endothelial function compared with TUVP. Therefore, iTUPKEP may reduce the incidence of postoperative cardiovascular adverse events in high-risk patients with BPH and coronary artery disease.Qingchao MengJingmei LiMingfeng LiRangxue QiuSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Qingchao Meng Jingmei Li Mingfeng Li Rangxue Qiu Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
description	Objective This prospective study aimed to evaluate the safety of improved transurethral plasma kinetic enucleation of the prostate (iTUPKEP) in the perioperative period in high-risk patients with benign prostatic hyperplasia (BPH) and coronary artery disease. Methods Patients with BPH underwent surgical treatment with transurethral vapour resection of the prostate (TUVP) or iTUPKEP. Serum endothelin-1, cardiac troponin-I, and high-sensitivity C-reactive protein concentrations were evaluated in the short term after surgery. The postvoid residual urine volume, maximum urinary flow rate, international prostate symptom score, and quality of life indicators were evaluated in the long term after surgery. Results Endothelin-1 concentrations were lower in the iTUPKEP group than in the TUVP group at 1 and 2 days postoperatively. The iTUPKEP group had lower cardiac troponin-I and high-sensitivity C-reactive protein concentrations at all time points postoperatively. The postvoid residual urine volume, international prostate symptom score, and quality of life values were lower, but the maximum urinary flow rate was higher, in the iTUPKEP group than in the TUVP group. Conclusions The iTUPKEP procedure has a smaller effect on vascular endothelial function compared with TUVP. Therefore, iTUPKEP may reduce the incidence of postoperative cardiovascular adverse events in high-risk patients with BPH and coronary artery disease.
format	article
author	Qingchao Meng Jingmei Li Mingfeng Li Rangxue Qiu
author_facet	Qingchao Meng Jingmei Li Mingfeng Li Rangxue Qiu
author_sort	Qingchao Meng
title	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
title_short	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
title_full	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
title_fullStr	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
title_full_unstemmed	Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
title_sort	evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/b7217ca13acf41048fd4d54bde72cede
work_keys_str_mv	AT qingchaomeng evaluationofefficacyandsafetyofimprovedtransurethralplasmakineticenucleationoftheprostateinhighriskpatientswithbenignprostatichyperplasiaandcoronaryarterydisease AT jingmeili evaluationofefficacyandsafetyofimprovedtransurethralplasmakineticenucleationoftheprostateinhighriskpatientswithbenignprostatichyperplasiaandcoronaryarterydisease AT mingfengli evaluationofefficacyandsafetyofimprovedtransurethralplasmakineticenucleationoftheprostateinhighriskpatientswithbenignprostatichyperplasiaandcoronaryarterydisease AT rangxueqiu evaluationofefficacyandsafetyofimprovedtransurethralplasmakineticenucleationoftheprostateinhighriskpatientswithbenignprostatichyperplasiaandcoronaryarterydisease
_version_	1718398682775158784

Evaluation of efficacy and safety of improved transurethral plasma kinetic enucleation of the prostate in high-risk patients with benign prostatic hyperplasia and coronary artery disease

Ejemplares similares